GSK PLC CEDEAR EACH REPR 1/4 ADR (USD)GG

GSK PLC CEDEAR EACH REPR 1/4 ADR (USD)

9.28USDD
−0.14−1.49%
At close at May 9, 19:39 GMT
USD
No trades
See on Supercharts

Key facts today


A lead plaintiff has been appointed in a class action lawsuit against GSK PLC, initiated by shareholders on February 4, 2025, over potential $5-$10 billion liabilities from Zantac lawsuits.
GSK has halted its belrestotug program with iTeos Therapeutics after phase 2 studies failed to show required efficacy. This impacts all related trials, including those for lung cancer.
GSK's trials for belrestotug with dostarlimab in lung cancer showed no significant gains in progression-free survival, and another trial reported low response rates in head and neck cancer.
Analyze the impactAnalyze the impact
Market capitalization
‪74.82 B‬USD
0.45USD
‪2.92 B‬USD
‪35.61 B‬USD
Beta (1Y)
0.05

About GSK PLC ORD GBP0.3125


CEO
Emma N. Walmsley
Website
Headquarters
London
ISIN
ARDEUT110483
FIGI
BBG003641ZB7
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Performance
‪−8%‬
‪0%‬
‪8%‬
‪16%‬
‪24%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−3.50 B‬‬
‪0.00‬
‪‪3.50 B‬‬
‪‪7.00 B‬‬
‪‪10.50 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪2.50 B‬‬
‪‪5.00 B‬‬
‪‪7.50 B‬‬
‪‪10.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪2.50 B‬‬
‪‪5.00 B‬‬
‪‪7.50 B‬‬
‪‪10.00 B‬‬
Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪6.00 B‬‬
‪‪12.00 B‬‬
‪‪18.00 B‬‬
‪‪24.00 B‬‬
Debt
Free cash flow
Cash & equivalents

No news here

Looks like there's nothing to report right now

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
GSK3981911
GlaxoSmithKline Capital, Inc. 4.2% 18-MAR-2043
Yield to maturity
6.09%
Maturity date
Mar 18, 2043
XS217060907
GLAXOSM.CAP. MTN 20/35MTN
Yield to maturity
6.06%
Maturity date
May 12, 2035
17RI
GLAXOSMITHKLINE CAPITAL PLC 4.25% GTD SNR EMTN 18/12/45
Yield to maturity
6.06%
Maturity date
Dec 18, 2045
83GI
GLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 10/04/2042
Yield to maturity
5.95%
Maturity date
Apr 10, 2042
71ZC
GLAXOSMITHKLINE CAPITAL PLC 6.375% GTD SNR EMTN 09/03/39
Yield to maturity
5.50%
Maturity date
Mar 9, 2039
GSK.GJ
GlaxoSmithKline Capital, Inc. 6.375% 15-MAY-2038
Yield to maturity
5.31%
Maturity date
May 15, 2038
GSK6023693
GlaxoSmithKline Capital, Inc. 4.875% 15-APR-2035
Yield to maturity
5.26%
Maturity date
Apr 15, 2035
AG99
GLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 19/12/2033
Yield to maturity
4.79%
Maturity date
Dec 19, 2033
GSK6023692
GlaxoSmithKline Capital Plc FRN 12-MAR-2027
Yield to maturity
4.74%
Maturity date
Mar 12, 2027
GSK6023695
GlaxoSmithKline Capital, Inc. 4.5% 15-APR-2030
Yield to maturity
4.68%
Maturity date
Apr 15, 2030
US377373AH8
GLAXOSM.CAP. 19/29
Yield to maturity
4.67%
Maturity date
Jun 1, 2029

See all GSKD bonds 

Curated watchlists where GSKD is featured.